推荐产品
品質等級
化驗
≥99% (HPLC)
形狀
powder
起源
Valeant
儲存溫度
2-8°C
SMILES 字串
Cl.COc1ccc(cc1)[C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O
InChI
1S/C22H26N2O4S.ClH/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;/h5-12,20-21H,13-14H2,1-4H3;1H/t20-,21+;/m1./s1
InChI 密鑰
HDRXZJPWHTXQRI-BHDTVMLSSA-N
基因資訊
human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
一般說明
盐酸地尔硫卓可用于治疗心血管疾病,例如心绞痛和高血压。它可充当细胞色素P450 3A(CYP3A)的抑制剂。地尔硫卓可能与斑丘疹、荨麻疹和瘙痒有关。
應用
(+)-顺式-盐酸地尔硫卓已用于:
- 研究其对整体分散基质(monolithic dispersion matrix)中扩散和释放的影响(26)
- 研究其在视网膜色素变性(RP)模型中的神经保护作用(27)
- 作为Cav1.2 L型钙通道(LTCC)的拮抗剂(28)
生化/生理作用
封闭缓慢或L-型Ca2+通道;调节来自中性粒细胞内存储的Ca2+的释放;刺激1,4-二氢吡啶结合至Ca2+通道;冠状动脉舒张剂。
特點和優勢
这种化合物是环核苷酸研究的特色产品。点击此处发现更多特色环核苷酸产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
其他客户在看
Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature
Archives of Dermatology, 142(2), 206-210 (2006)
Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting
Anesthesiology, 85(6), 1246-1252 (1996)
British journal of pharmacology, 127(2), 576-582 (1999-06-29)
1. The putative inhibitory effects of verapamil and diltiazem on neuronal non-L-type Ca2+ channels were studied by investigating their effects on either K+- or veratridine-evoked [3H]-dopamine ([3H]-DA) release in rat striatal slices. Involvement of N-, P- and Q-type channels was
The Journal of physiology, 519 Pt 3, 713-722 (1999-08-24)
1. To extend our knowledge of the site and mechanism of action of L-type Ca2+ channel antagonists on 5-HT3 receptors, whole-cell voltage clamp electrophysiology was used to investigate the action of one of these compounds, diltiazem, on the recombinant receptor
American heart journal, 164(3), 394-401 (2012-09-18)
No randomized trial has been conducted to compare different vasodilators for treating no-reflow during primary percutaneous coronary intervention (PCI) for ST-segment elevation acute myocardial infarction. The prospective, randomized, 2-center trial was designed to compare the effect of 3 different vasodilators
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门